Legend Capital, a subsidiary of Legend Holdings Ltd., was founded in April 2001 and is based in Beijing, China. The firm manages private equity investments across four funds, totaling up to US$700 million, focusing primarily on early-stage ventures and mid-market growth companies. Its investment strategy targets sectors including information technology, telecommunications, media, healthcare, consumer goods, clean technology, and advanced manufacturing, with a strong emphasis on businesses that are either based in China or related to Chinese markets. Legend Capital is known for its active involvement with portfolio companies, providing them with essential business resources and tailored services to enhance development and optimize company performance in the Chinese market. The firm has built a diverse portfolio of over 60 companies, contributing to its reputation as a respected player in China's venture capital industry.
MacroLux operates as a medical technology company focusing on endoscopic interventional business. MacroLux develops endoscopic interventional therapy solutions and promote them to the majority of medical customers.
ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.
Wuxi Biortus Biosciences Co. Ltd. is a contract research organization based in Jiangyin, China, specializing in research and development services that support drug discovery. Founded in 2009, the company offers a range of services including recombinant protein production, in vitro assays and screening, medicinal chemistry, structural biology, and target validation. These services are designed to assist pharmaceuticals, biotechnology firms, and research institutions in achieving their drug discovery objectives. Biortus has established five advanced research platforms and has developed innovative techniques, some of which are patented. The company operates as a subsidiary of Jiangsu Shuangliang Group Company Ltd.
H.Extract, established in 2010 and based in Qingdao, China, specializes in producing natural extracts from various spices such as pepper, ginger, garlic, and cumin for the food manufacturing sector. The company focuses on the research and development of high-quality extracts to meet the needs of food producers, enhancing flavor and nutritional value in their products. H.Extract is committed to maintaining industry standards and ensuring customer satisfaction through its innovative solutions and dedication to quality. With a growing reputation in the market, the company continues to expand its product offerings and strengthen its position within the food industry.
HC Scientific Technology Co., Ltd. is a company based in Chengdu, China, that specializes in the development, manufacturing, and distribution of genetic testing instruments, reagents, and software. Founded in 2015, the company serves various sectors, including clinical molecular diagnostics, health genetic testing, and agricultural molecular breeding, both domestically and internationally. HC Scientific's product lineup features instruments such as the Matrix Arrayer for reaction plate preparation, the Matrix Cycler for thermal cycling, and the Matrix Scanner for fluorescence detection. Additionally, the company provides consumables like the Matrix plate and Matrix Mix genotyping reagents, along with a data management system known as Matrix Master. Committed to innovation, HC Scientific focuses on autonomous research and development of its intellectual property, aiming to deliver high-throughput, automated, and cost-effective genetic testing solutions.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Developer of biotechnologies designed to drive new drugs research and development. The company allows scientists to model life more accurately from proteins to a system level and extract novel insights and predictions from limited data, supported by an international, cross-functional team, enabling physicians to enhance the effectiveness rate of new drugs.
Developer and producer of enzymes and antibodies designed to serve in life science industry. The company is committed to research and development of enzymes and antibodies and providing high-quality products and services including reverse transcription, molecular cloning, and cell culture, enabling life scientist to facilitate their field research and enhance the advancement of life science.
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.
Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.
Exegenesis Bio
Series B in 2021
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.
HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oral c-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.
Beijing Deepwise Science And Technology Co., Ltd. develops an artificial intelligence (AI) based medical application software that provides clinical imaging analysis and clinical diagnostics. The company offers early screening and diagnosis of various malignant diseases. It serves to hospitals, medical centers, and third party imaging centers. The company was founded in 2017 and is based in Beijing, China.
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
Beijing Genskey Technology Co., Ltd. is a medical diagnostic service provider specializing in genetic testing. Founded in 2007 and headquartered in Beijing, China, the company employs high-throughput sequencing technology combined with intelligent algorithm analysis to enhance pathogen diagnosis. Genskey aims to address common challenges in the medical diagnostics field, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of diagnostic results, Genskey seeks to ensure that patients suffering from severe infections receive prompt and accurate diagnoses, ultimately contributing to better health outcomes.
Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
China Diagnostic Medical Corporation (CDMC)
Private Equity Round in 2018
China Diagnostic Medical Corporation is a diagnostic testing reagents maker.
Beijing Chemclin Biotech Co., Ltd. specializes in the development, production, and sales of diagnostic reagents and instruments for clinical use. Founded in 1999 and based in Beijing, China, the company focuses on in-vitro diagnostics, offering a range of products including reagents for infectious diseases, tumor markers, and thyroid and diabetes testing. Chemclin also provides semi-automated and fully automated chemiluminescent analyzers, which facilitate the performance of chemiluminescent assays. Additionally, the company offers commercial testing services for various health conditions, including liver fibrosis and fertility. As a subsidiary of China Diagnostics Medical Corporation, Chemclin is committed to delivering innovative diagnostic solutions and services to the Chinese healthcare market.
Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.
Enjoy Dental Clinic, founded in 2007 and based in Beijing, China, specializes in providing dental care services. The clinic offers a range of dental treatments while also focusing on dental clinic franchising. This includes providing essential services such as dental training, clinic construction, and investment support. Through these offerings, Enjoy Dental Clinic enables aspiring dentists to gain professional training and operational experience in running a dental practice.
Yosemite Clinic is a multidisciplinary medical center located in Central Pudong, Shanghai, offering a wide range of walk-in services in a modern and well-equipped environment. The clinic provides specialties including family medicine, internal medicine, gynecology, pediatrics, rehabilitation, sports medicine, dentistry, ophthalmology, dermatology, and medical cosmetology. It is particularly noted for its focus on Minimally Invasive Surgery and Ambulatory Surgery. The facility is equipped with advanced medical imaging technology, including CT, X-ray, and ultrasound, alongside a fully operational laboratory and pharmacy. The clinic's diverse team of healthcare professionals hails from both China and around the world, allowing them to offer services in multiple languages such as English, Japanese, Malay, Mandarin Chinese, and Cantonese, ensuring comprehensive care for a diverse patient population.
Beijing Deepwise Science And Technology Co., Ltd. develops an artificial intelligence (AI) based medical application software that provides clinical imaging analysis and clinical diagnostics. The company offers early screening and diagnosis of various malignant diseases. It serves to hospitals, medical centers, and third party imaging centers. The company was founded in 2017 and is based in Beijing, China.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Ayshealth Technology develops chronic disease management system. It offers Guideline-based Decision Support (GDS) that assists and guides assist physicians and other health service providers with cloud services and professional medical support. The company was founded in 2014 and is based in Beijing, China
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
Indi Molecular, Inc. is a life sciences company based in Culver City, California, that specializes in developing a synthetic class of diagnostic and therapeutic agents known as protein-catalyzed capture (PCC) agents. Founded in 2013 as a spinout from Integrated Diagnostics, the company utilizes “click chemistry” to create PCCs, which possess antibody-like properties with advantages such as improved selectivity, superior binding affinity, and significantly lower molecular weight compared to traditional monoclonal antibodies. These agents serve a dual purpose, functioning as precision-targeted therapeutics and in vivo imaging agents, enhancing the identification of biomarkers in diagnostics and therapeutic applications. The development of PCCs was a collaborative effort with the California Institute of Technology, reflecting the company's commitment to innovation in the life sciences sector.
Qiang Sen International Community Medical (QSICM) operates community healthcare service centers. The Clinic offers internal medicine, pediatrics, gynecology, stomatology, laboratory, ultrasonography, and electrocardiography services. QSICM serves patients in China.
POCTech Corporation, founded in 2010 and headquartered in Huzhou, China, specializes in the research, development, manufacturing, and marketing of point-of-care testing (POCT) systems focused on diabetes management. The company offers a range of products, including continuous glucose monitoring systems equipped with soft sensors, as well as handheld devices for blood gas and electrolyte analysis. These portable monitoring devices are designed for use in various medical settings, such as clinics and ambulances, allowing patients to conveniently and effectively monitor their diabetes. By leveraging advanced biological sensor technology, POCTech aims to enhance the quality of care for diabetes patients through innovative and accessible medical solutions.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Operator of a neurology clinic. The clinic specializes in neurosurgery, brain tumor treatment and epilepsy treatment, enabling patients to obtain expert, specialized care.
Qiang Sen International Community Medical (QSICM) operates community healthcare service centers. The Clinic offers internal medicine, pediatrics, gynecology, stomatology, laboratory, ultrasonography, and electrocardiography services. QSICM serves patients in China.
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.
Developer and supplier of a full range of in vitro diagnostic(IVD) equipment designed to improve clinical decision making and treatment pathways. The company's products include chemistry analyzer and PCR analyzer using microfluidics technology, providing medical industry with efficient IVD tests and reduced healthcare spending.
POCTech Corporation, founded in 2010 and headquartered in Huzhou, China, specializes in the research, development, manufacturing, and marketing of point-of-care testing (POCT) systems focused on diabetes management. The company offers a range of products, including continuous glucose monitoring systems equipped with soft sensors, as well as handheld devices for blood gas and electrolyte analysis. These portable monitoring devices are designed for use in various medical settings, such as clinics and ambulances, allowing patients to conveniently and effectively monitor their diabetes. By leveraging advanced biological sensor technology, POCTech aims to enhance the quality of care for diabetes patients through innovative and accessible medical solutions.
BioNanomatrix, Inc. develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications.
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
DXY is a social media platform focused on the pharmaceuticals and life sciences sectors, facilitating communication among healthcare professionals and the public. Founded by Li Tiantian in July 2000 and headquartered in Hangzhou, China, DXY serves over three million registered members. The platform features informative articles on the latest research and general health advice, promoting knowledge exchange among physicians and life science professionals. Additionally, DXY offers precision digital marketing services and public health resources online, aimed at enhancing user productivity and engagement within the healthcare community.
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.
Founded in May 2010, Berry Genomics is the leading genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
CareRay Digital Medical Technology Co Ltd specializes in the development and production of advanced flat panel detectors for digital X-ray imaging systems. Their products are utilized across various sectors, including medical, veterinary, security, and industrial applications. CareRay's extensive product portfolio encompasses a range of imaging solutions such as radiography, mammography, fluoroscopy, and dental imaging, along with various associated accessories. The company is committed to innovation, aiming to enhance diagnostic capabilities through the latest technological advancements in imaging.
CareRay Digital Medical Technology Co Ltd specializes in the development and production of advanced flat panel detectors for digital X-ray imaging systems. Their products are utilized across various sectors, including medical, veterinary, security, and industrial applications. CareRay's extensive product portfolio encompasses a range of imaging solutions such as radiography, mammography, fluoroscopy, and dental imaging, along with various associated accessories. The company is committed to innovation, aiming to enhance diagnostic capabilities through the latest technological advancements in imaging.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.